Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capizzi vs High Dose Methotrexate in Pediatric T-LBL
NCT05681260Phase 3Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of methotrexate in T cell lymphoblastic lymphoma (T-LBL) (3 arms), sponsored by Children's Oncology Group. Primary endpoints: Event Free Survival for standard risk patients at 4 years, Event Free Survival according to bone marrow MDD at 4 years and 1 more. Started Feb 2023; status: recruiting.
02
Drugs
methotrexate
03
Conditions
T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT05681260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05681260.